Shares of enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) have received a consensus rating of “Buy” from the seven ratings firms that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have covered the stock in the last year is $33.67.
Several research firms have recently weighed in on ENGN. Oppenheimer reiterated an “outperform” rating and issued a $30.00 price objective on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reiterated an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research note on Wednesday, September 11th.
View Our Latest Analysis on enGene
enGene Trading Up 2.1 %
enGene (NASDAQ:ENGN – Get Free Report) last posted its quarterly earnings results on Tuesday, September 10th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.05. As a group, equities analysts forecast that enGene will post -1.56 EPS for the current year.
Insider Buying and Selling
In other enGene news, CEO Ronald Harold Wilfred Cooper purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average cost of $5.70 per share, for a total transaction of $57,000.00. Following the transaction, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $57,000. The purchase was disclosed in a filing with the SEC, which is available through this link. 13.70% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On enGene
A number of large investors have recently bought and sold shares of ENGN. Janus Henderson Group PLC bought a new stake in enGene during the 1st quarter worth approximately $17,095,000. SR One Capital Management LP bought a new position in enGene in the 2nd quarter valued at $4,715,000. Logos Global Management LP boosted its position in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after buying an additional 400,000 shares during the last quarter. Finally, Altitude Crest Partners Inc. bought a new position in enGene in the 1st quarter valued at $2,039,000. 64.16% of the stock is currently owned by institutional investors.
About enGene
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Featured Articles
- Five stocks we like better than enGene
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What Are Trending Stocks? Trending Stocks Explained
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.